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Malignant transformation of melanocytes is frequently
associated with abnormalities in antigen processing
and in human leukocyte antigen class I antigen expres-
sion. Here, we evaluated a human leukocyte antigen
class I antigen-independent approach to target cyto-
toxic T lymphocytes to melanoma cells by grafting
cytotoxic T lymphocytes with a chimeric receptor that
consists of both a domain binding to high molecular
weight-melanoma associated antigen and a cellular
activation domain. The binding domain is a single-
chain antibody fragment (scFv) derived from the
monoclonal anti-high molecular weight-melanoma
associated antigen antibody 763.74 by phage display
techniques. The cellular activation domain is the sig-
naling unit of the FceRI receptor g chain. Both domains
In recent years there has been a growing interest in theapplication of immunotherapy for the treatment of melan-oma. This trend reflects, at least in part, the disappointingresults of conventional chemotherapy (Koh, 1991), theidentification of melanoma-associated antigens (MAA) suit-
able to be used as targets for immunotherapy (Boon, 1994;
Rosenberg, 1996), and the significant progress in our understanding
of the molecular steps leading to the development of an immune
response (Brodsky et al, 1996). Because of the general belief that
T cell immunity plays a major part in the control of tumor growth
(McMichael, 1992), the emphasis has been on the application of
T cell based immunotherapy. The latter is negatively affected by
abnormalities in human leukocyte antigen (HLA) class I antigen
presentation and in antigen processing which occur frequently in
malignant cells (Ferrone and Marincola, 1995; Seliger et al, 1997).
Therefore, methods are being developed which target T cells to
tumor cells bypassing the requirements of presentation of tumor-
Manuscript received October 28, 1998; revised January 25, 1999;
accepted for publication February 2, 1999.
Reprint requests to: Dr. Uwe Reinhold, Department of Dermatology,
The Saarland University Hospital, Homburg/Saar, Oscar-Orth-Str., D-
66421 Homburg/Saar, Germany.
Abbreviations: CTL, cytotoxic T cells; HMW-MAA, high molecular
weight melanoma-associated antigen; id, idiotypic; scFv, single-chain anti-
body fragment; TAA, tumor-associated antigen.
0022-202X/99/$10.50 · Copyright © 1999 by The Society for Investigative Dermatology, Inc.
744
constitute the chimeric receptor scFv763.74-gR. Cyto-
toxic MD45 T cells grafted with the scFv763.74-gR
receptor bind specifically to high molecular weight-
melanoma associated antigen-positive melanoma cells
and lyse melanoma cells in a human leukocyte antigen
class I independent fashion. Pre-incubation of receptor
grafted T cells with immobilized anti-idiotypic (id)
monoclonal antibody MK2–23 binding to the scFv
domain of the receptor enhanced the lysis of melanoma
cells indicating that the specific cytolytic activity of
receptor grafted T cells can be increased by costimula-
tion with cross-linked anti-idiotypic monoclonal anti-
bodies that recognize the antigen binding domain of
the chimeric receptor. Key words: anti-idiotypic mono-
clonal antibody/cellular targeting/chimeric T cell receptor.
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associated antigen (TAA) derived peptides by HLA class I antigens
to T cell receptors. Among these approaches some were developed
by Eshhar and his collaborators (Gross and Eshhar, 1992), which
has attracted much interest. Using this methodology cytotoxic T
lymphocytes (CTL) are targeted to tumor cells by grafting a
chimeric receptor. Its extracellular moiety is composed of the
variable regions of the heavy and light chain of an antibody
recognizing a TAA. Its intracellular moiety consists of a signal
transduction chain for specific cellular activation. Early studies
proved the validity of the approach by showing that grafting with
a chimeric receptor specific for TNP endowed CTL with a non-
major histocompatibility complex restricted recognition of TNP
bearing target cells (Gross et al, 1989). More recently, chimeric
receptors have been constructed with single chain fragments of
variable regions (scFv) derived from monoclonal antibody (MoAb)
recognizing human TAA (Abken et al, 1998). They include ErbB-
2 (Stancovski et al, 1993; Moritz et al, 1994), 38 kDa folate binding
protein (Hwu et al, 1993), G250 (Weijtens et al, 1996), CD30
(Hombach et al, 1998a), TAG72 (Hombach et al, 1997), membrane-
bound CEA (Hombach et al, 1998b), and CD44v6 splice variants
(Hekele et al, 1996). Effector cells transfected with the respective
chimeric receptor have been shown to acquire the ability to
lyse tumor cells expressing the appropriate TAA in a major
histocompatibility complex unrestricted fashion.
In this study we have constructed a melanoma cell specific,
chimeric receptor utilizing scFv fragments derived from the mouse
anti-human high molecular weight-melanoma associated antigen
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(HMW-MAA) MoAb 763.74. This antigen seems to be suitable
for an immunotherapeutic approach as it is expressed in a large
percentage of melanoma lesions (Ferrone et al, 1988), has a restricted
distribution in normal tissues, and has already been used successfully
as target of active and specific immunotherapy in melanoma (Spitler
et al, 1987; Mittelman et al, 1990). We therefore demonstrate that
cytotoxic T cells grafted with the anti-HMW-MAA receptor are
activated to specific, major histocompatibility complex-unrestricted
cellular cytotoxicity against HMW-MAA1 melanoma cells and
that the cytolytic activity can be increased by anti-idiotypic (id)
antibodies that recognize the antigen-binding domain of the grafted
chimeric receptor.
MATERIALS AND METHODS
Cell lines and cell lysate The mouse hybridoma cells which secrete
the anti-HMW-MAA MoAb 763.74, the human melanoma cell lines Colo
38 and SK-MEL-5, a subclone of the human melanoma cell line A375,
the MD45 alloreactive cytotoxic T hybridoma cells (Kaufmann et al, 1981)
of BALB/C origin and the MD45 cells transfected with the unrelated scFv
CD30R (chimeric receptor clone HRS-3γC1) (Hombach et al, 1998a)
were cultured in medium RPMI 1640 (Gibco, Paisley, U.K.) supplemented
with 10% fetal bovine serum (PAA Laboratories, Linz, Austria), penicillin
(100 U per ml; Biochrom, Berlin, Germany), streptomycin (100 µg per ml;
Biochrom), and 2 mM L-glutamine (Biochrom). All cell lines were
maintained in a 5% CO2 humidified incubator at 37°C. A lysate of
melanoma cells Colo 38 was prepared by incubating cells (1 3 107) for
30 min on ice in 1.2 ml of lysis buffer (ethylenediamine tetraacetic acid
1 mM, NaCl 150 mM, Tris base 10 mM, 1% NP40) containing 10 mM
phenylmethylsulfonyl fluoride. Supernatant was collected after centrifuga-
tion at 10,000 3 g for 30 min and stored at –20°C.
Synthetic oligonucleotide primers and Fc receptor g chain
cDNA Primers used for polymerase chain reaction amplification of
cDNA of VH and VL domains of MoAb 763.74 were purchased from
Pharmacia (Freiburg, Germany). Oligonucleotide primers VH54 (59GCG
GCC CAG TCT AGA ATG GCC CAG 39) and E-tag/VL34 (59GGT
TCC AGC GGA TCC GGA TAC GCG 39) used for the introduction of
restriction sites at the ends of the scFv were synthesized by the phosphoamid-
ite procedure (Caruthers et al, 1987) using an Expedite Synthesizer
(Millipore, Eschborn, Germany). DNA sequences were determined by the
chain termination method (Sanger et al, 1977) using the ABI Model 377
automatic sequencing system. The pRSV-γ vector (Eshhar et al, 1993)
containing the FcεRI γ chain under the control of the RSV LTR
was kindly provided by Dr. Z. Eshhar (Weizman Institute of Sciences,
Rehovot, Israel).
Monoclonal antibodies, scFv fragments, and conventional
antisera The 120 kDa MAA binding scFv W34 was isolated from a
semisynthetic scFv library by panning with cultured human melanoma cells
WM1158 (X. Wang and S. Ferrone, unpublished results). scFv HRS-3
fragments were generated from anti-CD30 MoAb HRS-3 as described
(Hombach et al, 1998a). The mouse MoAb 225.28, TP41.2, and 763.74
recognizing spatially distant antigenic determinants of HMW-MAA, the
mouse anti-id MoAb MK2–23 generated from a BALB/C mouse immun-
ized with MoAb 763.74 and the mouse anti-id MoAb TK7–371 recognizing
an idiotope in the antigen combining site of the immunizing syngeneic
anti-HMW-MAA MoAb TP61.5 were developed as described (Wilson
et al, 1981; Giacomini et al, 1983; Kusama et al, 1989; Chen et al, 1991;
Temponi et al, 1992). MoAb were purified from ascitic fluid by sequential
precipitation with caprylic acid and ammonium sulfate (Temponi et al,
1989). The purity and activity of MoAb preparations were monitored by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (Laemmli, 1970)
and by binding assays with the corresponding antigen, respectively. Anti-
E Tag MoAb and horseradish peroxidase (HRP)-conjugated anti-E Tag
MoAb were purchased from Pharmacia. Rat anti-mouse interleukin (IL)-
2 MoAb and biotinylated rat anti-mouse IL-2 MoAb were purchased from
Pharmingen (San Diego, CA). Goat anti-mouse IgG antibodies, fluorescein
isothiocyanate (FITC)-conjugated anti-mouse IgG xenoantibodies and
HRP-conjugated anti-mouse IgG xenoantibodies were purchased from
Immunotech (Hamburg, Germany).
Construction and expression of the scFv763.74 RNA was extracted
from the 763.74 hybridoma cells by the acid–guanidium–thiocyanate–
chloroform method. First-strand cDNA synthesis and amplification of the
Fv-encoding regions were carried out utilizing the recombinant phage
antibody system (Pharmacia) following the supplier’s instructions. The VH
and VL cDNA fragments were fused via the (Gly4Ser)3 peptide linker in
VH-VL order, introducing an Sfi and a NotI restriction site at the 59 and
39 end of the scFv, respectively. The scFv cDNA was amplified by
polymerase chain reaction utilizing primer VH54 and E-tag/VL, digested
with Sfi and NotI, and inserted into the phagemid pCANTAB5E DNA
(Pharmacia). Phages expressing the 763.74 scFv were selected by panning
on immobilized anti-id MoAb MK2–23. To this end, cell culture flasks
were coated with anti-id MoAb MK2–23 (10 µg per ml) at 4°C overnight.
Following three washings the culture flasks were blocked with phosphate-
buffered saline (PBS)/bovine serum albumin (BSA) (5%) and then incubated
for 2 h at room temperature with the supernatant containing the phages.
Finally, the flask was washed 40 times with PBS/Tween 20 (0.1%). TG1
cells were infected with phages and plated out on 2 3 YT-medium
containing 100 mM glucose and ampicillin (100 µg per ml). Individual
colonies were transferred to microtiter plates and phages were rescued by
overnight incubation in 2 3 YT-medium (without glucose) supplemented
with ampicillin (100 µg per ml) and kanamycin (50 µg per ml). The
scFv protein was expressed by inducing with 1.0 mM isopropyl-β-D-
thiogalactopyranoside at 25°C a colony of Escherichia coli HB2151 cells
transformed with the recombinant phagemid and grown at 37°C in 2xyT
medium containing 0.1% glucose and 100 µg ampicillin per ml to an
OD600 of 1.0. Cells were harvested from 1 liter of bacterial culture by
centrifugation at 4000 3 g for 15 min at 4°C and lysed. The lysate was
centrifuged at 8000 3 g for 30 min at 4°C. The supernatant was dialyzed
against PBS and tested for content of scFv fragments.
Western blotting Proteins of bacteria extracts containing the scFv were
electrophoretically separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and blotted on to nitrocellulose membrane. Following an
overnight incubation at room temperature in 4% BSA/PBS, the blot was
incubated for 1 h at room temperature with HRP-conjugated anti-E tag
MoAb solution (1 µg 4% BSA/PBS per ml; Pharmacia). Following six
washings with PBS, binding of HRP-labeled anti-E-tag MoAb was
visualized using 4-chloro-1-naphtol substrate (Sigma, Deisenhofen,
Germany) and 0.03% H2O2.
Coating of microtiter plates with HMW-MAA, MoAb, F(ab9)2, and
scFv fragments Ninety-six well microtiter plates (Nunc, Roskilde,
Denmark) were coated with HMW-MAA as previously described (Chen
et al, 1991). Briefly, microtiter plates were coated with anti-HMW-MAA
MoAb 225.28 by adding 100 µl of a MoAb solution (either 10 µg NaHCO3
per ml, pH 9.6 or 2 µg PBS per ml, pH 7.4) to each well. Following an
overnight incubation at room temperature, plates were washed three times
with PBS and blocked with 2% BSA/PBS for 1 h at room temperature.
A melanoma cell lysate (100 µl) was added to each well following an
overnight incubation at room temperature, plates were washed three times
with PBS. Plates were coated with the whole IgG or F(ab9)2 fragments of
MoAb or with scFv fragments by adding to each well 100 µl of a MoAb
whole IgG or F(ab9)2 fragment solution (10 µg NaHCO3 per ml, pH 9.6)
or of a scFv fragment solution (20 µg PBS per ml, pH 7.4), respectively.
At the end of an overnight incubation at 4°C, plates were washed twice
with PBS and blocked with 4% BSA/PBS.
Serologic assays The enzyme-linked immunosorbent assay (ELISA) to
measure the reactivity of scFv763.74 fragments with HMW-MAA and
with anti-id MoAb was performed in 96 well microtiter immunoplates
(Nunc) coated with HMW-MAA or with scFv fragments. One hundred
microliters of 2-fold dilutions of a scFv763.74 solution (20 µg PBS per ml)
or of spent medium of anti-id MoAb secreting hybridomas were added to
each well and the mixture was incubated for 2 h at room temperature.
Following three washings, HRP-conjugated anti-E-tag MoAb or HRP-
conjugated anti-mouse IgG Fc xenoantibodies were added and incubation
was continued for an additional 2 h at room temperature. Following three
washings, 2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid (Sigma) and
0.03% H2O2 in citrate buffer were added. Following a 30 min incubation
at room temperature the reaction was stopped by adding 100 liters of
sodium dodecyl sulfate/N,N-dimethyl formamide solution to each well.
Absorbance was read at 405 nm utilizing a microtiter plate ELISA reader
(SLT-Labinstruments, Crailsheim, Germany). Results are expressed as mean
optical density (OD) units. All assays were done in triplicate.
The inhibition assay to measure the ability of anti-id MoAb to inhibit
the binding of MoAb 763.74 and scFv763.74 to melanoma cells Colo 38
and to anti-id MoAb MK2–23 was performed as described (Perosa et al,
1989). The competition ELISA to map the antigenic determinant recog-
nized by scFv763.74 was performed by adding 100 µl of a MoAb 763.74
solution (1 µg PBS per ml) to MoAb MK2–23 coated wells. Following a
1 h incubation at room temperature and two washings 100 µl of 2-fold
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dilutions of a scFv763.74 solution (1 µg PBS per ml) were added to a
microtiter plate. Results are expressed as mean OD units. The specificity
of the inhibition was monitored utilizing HRP-conjugated anti-E-tag
MoAb. Binding of scFv fragments was detected by adding sequentially
HRP-conjugated anti-E-Tag MoAb and citrate buffer supplemented with
2,29-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid and 0.03% H2O2.
The reaction was then stopped and absorbance was read at 405 nm with
an ELISA reader.
Indirect immunofluorescence (IIF) staining was performed by incubating
cells (1 3 105) sequentially either with scFv fragments (1 µg per ml) and
FITC-conjugated anti-E tag MoAb (1 µg per ml) or with anti-id MoAb
and FITC-conjugated anti-mouse IgG Fc xenoantibodies. Each incubation
was performed for 30 min at 4°C. Anti-id MoAb to unrelated MoAb were
used as controls. Fluorescence was excited at 488 nm with a 15-mW Argon
laser (FACScan; Becton Dickinson, Heidelberg, Germany). Fluorescence
intensity of 5000 cells per probe was monitored.
The double determinant immunoassay to measure IL-2 content in
medium was performed in microtiter immuno plates (Nunc) coated with
anti-IL-2 MoAb (2 µg PBS per ml). Supernatants from lymphocyte cultures
(100 µl per well) were added to plates in triplicate. At the end of a 4 h
incubation at room temperature, plates were washed and incubated for 1 h
at room temperature with 100 µl per well of a biotinylated rat anti-mouse
IL-2 MoAb solution (1 µg PBS per ml). Plates were then washed five
times with PBS and incubated for 1 h at room temperature with avidin-
conjugated peroxidase. Reaction was developed in presence of 2,29-Azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid in citrate buffer containing 0.03%
H2O2. The absorbance at 405 nm was determined with a microtiter plate
ELISA reader. Results are expressed as OD units.
Construction and expression of chimeric scFv763.74-gR cDNA
constructs The cDNA coding for the chimeric scFv763.74-γR was
constructed by introducing the Xbal and the BamHI restriction sites in the
flanking regions of the 763.74 scFv cDNA and by ligation into the pRSV-
γ vector. The scFv763.74 DNA was amplified from RNA of 763.74
hybridoma cells by reverse transcription–polymerase chain reaction using
the VH54 and E-tag/VL34 oligonucleotides as primers. The latter primers
introduce a Xbal site and a BamHI site, respectively. After digestion with
BamHI/XbaI, the scFv763.74 DNA was ligated in frame to the γ-chain
cDNA resulting in a DNA coding for scFv763.74-γ chimeric receptor.
The DNA sequences were determined by the chain termination method
(Sanger et al, 1977) using the ABI 100 Model 377 automatic sequencing
system. The MD45 hybridoma cells were transfected by single pulse
electroporation (250 V, 2400 µF; BioRad, Munich, Germany) with 100 µg
of the recombinant DNA. Cells were grown for 2 wk in the presence of
G418 (geneticin, 2 mg per ml; Sigma). Subsequently, transfected cells were
cloned by limiting dilution at 0.3 cells per well. Growing cells were
cultured in medium RPMI 1640 supplemented with 10% fetal bovine
serum and geneticin (2 mg per ml). Cultures were subcultured when the
cell density was higher than 1 3 106 per ml.
51Cr-release-assay Target cells (3 3 106 cells) were labeled with 150 µCi
of 51Cr (Amersham Buchler, Braunschweig, Germany) for 1 h at 37°C.
Following three washings with PBS, 51Cr-labeled target cells (5 3 103
cells) were incubated for 16 h at 37°C with effector cells at the ratio of
20:1, 10:1, 1:1, and 0.1:1 in a total volume of 200 µl. Supernatant (100 µl)
was then harvested by centrifugation and assayed for radioactivity by γ-
spectrophotometry. Specific cytotoxicity (%) was calculated by the following
formula: % cytotoxicity 5 (experimental cpm – spontaneous cpm) 3 100/
(total cpm – spontaneous cpm). Maximum and spontaneous release were
measured by counting the radioactivity in medium harvested from a
suspension of radiolabeled cells treated with 1% Triton X-100 (Sigma) and
of radiolabeled target cells, respectively.
RESULTS
Cloning of the HMW-MAA binding scFv763.74 The 763.74
scFv fragment was derived from the anti-HMW-MAA MoAb
763.74 by ligation of the VH and VL DNA fragments via a peptide
coding linker as described in Materials and Methods. The VH region
nucleotide sequence of the scFv763.74 is identical to that of the
parental MoAb, whereas the VL region nucleotide sequence of the
scFv763.74 is different at two positions without amino acid change
(Fig 1). The scFv763.74 DNA (750 bp) was inserted into phagemid
vector pCANTAB5E in frame with the M13 gene 3 and the Etag
DNA. Phages displaying the scFv763.74-gp3 fusion protein at their
surface were enriched by panning on the anti-id MoAb MK2–23,
which had been elicited with MoAb 763.74. The scFv763.74 is
approximately 34 kDa in size under reducing conditions as detected
by western blot analysis using anti-E tag MoAb (Fig 2).
The scFv763.74 retained the specificity of the parental MoAb
763.74 as it displayed specific reactivity in ELISA with a protein
extract from the HMW-MAA bearing SK-MEL-5 melanoma cells
and with the anti-id MoAb MK2–23. In addition, scFv763.74
stained SK-MEL-5 cells specifically in IIF (Fig 3). In competition
experiments the parental MoAb 763.74 inhibited binding of scFv
fragments to anti-id MoAb MK2–23 (Fig 4). As expected, the
parental MoAb 763.74 and scFv763.74 compete in binding to
melanoma cells Colo 38 (Fig 5). Two lines of evidence indicate
that the reciprocal inhibitions are specific. First, parental MoAb
763.74 and scFv763.74 did not inhibit the binding to Colo 38 cells
of the unrelated scFv W34 and of anti-HMW-MAA MoAb 225.28,
respectively. Second, the binding to Colo 38 cells of parental
MoAb 763.74 and of scFv763.74 was not affected by scFv W34
and by anti-HMW-MAA TP41.2, respectively. It is noteworthy
that MoAb 225.28 and TP41.2 recognize antigenic determinants
spatially distant from that recognized by MoAb 763.74 (Wilson
et al, 1981).
Construction and expression of the chimeric HMW-MAA
specific receptor The HMW-MAA specific receptor was con-
structed by fusing the scFv763.74 DNA in frame to the cDNA for
the transmembrane and signaling part the FcεRI receptor γ-chain
resulting in a γ-chain signaling receptor with an extracellular
scFv763.74 domain. After transfection, MD45 cells expressing
scFv763.74-γR were identified by IIF staining with anti-id MoAb
MK2–23 (Fig 6). IIF staining is specific as transfected cells were
not stained by the irrelevant anti-id MoAb TK7–371 and by anti-
mouse IgG xenoantibodies. Furthermore, MoAb MK2–23 did not
stain the parental MD45 T cells.
MD45 cells transfected with the chimeric scFv763.74-gR
are activated by the anti-id MoAb MK2–23 The receptor-
mediated cellular activation, indicated by increase in IL-2 secretion,
was tested by incubation of transfected MD45 T cells on plates
coated with anti-id MoAb MK2–23. As shown in Fig 7, receptor
grafted MD45 cells secrete increased amounts of IL-2 in a time-
dependent fashion. Increase in IL-2 secretion is specific, as only
background levels of IL-2 were found in medium harvested (i)
from transfected MD45 cells incubated in plates coated with
the irrelevant anti-id MoAb TK-371, and (ii) from parental,
untransfected MD45 cells incubated in plates coated with anti-id
MK2–23. It is noteworthy that soluble MoAb MK2–23 did not
stimulate IL-2 secretion from transfected MD45 cells.
Lysis of HMW-MAA bearing melanoma cells by MD45 cells
transfected with the chimeric scFv763.74-gR Transfected
MD45 cells lysed HMW-MAA positive SK-MEL-5 melanoma
cells whereas the parental MD45 cells did not lyse SK-MEL-5 cells
(Fig 8). MAA negative A375 cells are not lysed by anti-HMW-
MAA receptor grafted MD45 cells (data not shown). Furthermore,
transfected MD45 cells expressing the unrelated scFv HRS3-γ
receptor (clone scFv HRS-3γC1) did not lyse SK-MEL-5 cells.
The extent of lysis of melanoma cells by MD45 cells expressing
the scFv763.74-γR is at most 10%. We therefore tested whether
anti-id MoAb that bind to the scFv domain of the receptor could
enhance the cytotoxic activity of transfected MD45 cells. As shown
in Fig 9, transfected MD45 cells incubated in anti-id MoAb MK2–
23-coated plates displayed a marked increase in their ability to lyse
SK-MEL-5 cells. The effect is concentration dependent, as the
cytotoxicity increased from 3% to 25% by increasing the concentra-
tion of MoAb MK2–23 (0.01 µg per ml to 1 µg per ml) used to
coat the plate. The enhancing effect of MoAb MK2–23 is specific,
as incubation of transfected MD45 cells in plates coated with the
unrelated anti-id MoAb TK7–371 had no detectable effect on their
cytotoxic activity (Fig 9). The enhancement of cytotoxicity induced
by MoAb MK2–23 is mediated by the transfected scFv763.74-γR,
whereas parental MD45 cells incubated in MoAb MK2–23 coated
plates did not acquire the ability to lyse HMW-MAA bearing
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Figure 1. DNA sequences of the VH
and VL domains from the scFv763.74
and the parental 763.74 MoAb. VH and
VL represent the cDNA sequences for the
VH and VL domains, respectively, the hinge
region represents a peptide coding synthetic
linker sequence. The deduced amino acid
sequence of scFv763.74 is shown.
Figure 2. Immunoblot analysis of scFv763.74. E. coli HB2151 bacteria
were transfected with scFv763.74 DNA expression construct that contains
an E-tag fused to the 39 end of the scFv. Proteins from periplasmic extracts
of transfected (lanes 1 and 2) and nontransfected (lane 3) E. coli cells were
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
blotted onto a nitrocellulose membrane. The scFv763.74 protein was
detected by anti-E-tag MoAb.
melanoma cells. Immobilization of anti-id MoAb MK2–23 is
required for enhancement of the cytotoxic activity of transfected
MD45 cells, as their cytotoxic activity following a 48-h incubation
at 37°C in a solution of MoAb MK2–23 (10 µg per ml) is not
altered. The enhancing effect of immobilized anti-id MoAb MK2–
23 is similar to that of immobilized HMW-MAA, as transfected
MD45 cells incubated for 48 h at 37°C in HMW-MAA coated
microtiter plates lysed melanoma cells SK-MEL-5 to an extent
Figure 3. FACS analysis of the reactivity of scFv763.74 with SK-
MEL-5 melanoma cells. Cells were sequentially incubated with
scFv763.74 and FITC-conjugated anti-E tag MoAb (solid line). Stained
cells were analyzed by flow cytometry. scFv HRS-3 derived from anti-
CD30 MoAb HRS-3 (dotted line) was used as a negative control.
similar to that of transfected MD45 cells incubated with insolubilized
MoAb MK2–23 (Fig 10). It is noteworthy that incubation with
HMW-MAA positive Colo38 melanoma cells for 48 h at 37°C
had no detectable effect on the cytolytic activity of transfected
MD45 cells. This finding in conjunction with the results of the
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Figure 4. Mapping of the idiotope recognized on anti-id MoAb
MK2–23 by scFv763.74 and by parental MoAb 763.74. Serial dilutions
of the scFv763.74 were added to wells coated with the anti-id MoAb
MK2–23 without (d) or together with (s) the parental MoAb 763.74 as
competitor. The amount of specifically bound scFv763.74 was detected by
incubation with the anti-E-tag MoAb followed by HRP-conjugated goat
anti-mouse IgG antibodies.
Figure 5. Mapping of the determinants recognized by scFv763.74
and by parental MoAb 763.74 on cultured human melanoma cells
Colo 38. Melanoma cells Colo 38 (2 3 105 per well) were incubated for
2 h at 4°C with 2-fold dilutions of F(ab9)2 fragments of MoAb 763.74 (A;
d) or of scFv763.74 (B; d). In (A), cells were sequentially incubated for
2 h at 4°C with scFv763.74 (6 µg per ml) and for 1 h at 4°C with anti-E
tag MoAb (2 µg per ml). In (B), cells were incubated for 2 h at 4°C with
MoAb 763.74 (100 ng per ml). Following washing with PBS/1% BSA,
cells were incubated for 1 h at 4°C with HRP-conjugated goat anti-mouse
IgG antibodies. scFv763.74 incubated with Colo 38 cells preincubated
with F(ab9)2 fragments of MoAb 225.28 (A; s), scFv W34 incubated with
Colo 38 cells preincubated with F(ab9)2 fragments of MoAb 763.74 (A;
j), MoAb TP41.2 incubated with Colo 38 cells preincubated with
scFv763.74 (B; s) and MoAb 763.74 incubated with Colo 38 cells
preincubated with scFv W34 (B; j) were used as controls.
concentration-dependent enhancement of MD45 cell cytotoxicity
by anti-id MoAb MK2–23 (Fig 9) suggest that the level of HMW-
MAA expression on Colo 38 cells does not reach the minimum
required to trigger significant activation of the chimeric receptor
signaling pathway.
DISCUSSION
We have constructed a chimeric receptor by combining the
specificity of anti-HMW-MAA MoAb 763.74 with the signal
transduction capability of the FcεRI γ-chain. Transfection of the
chimeric scFv763.74-γR into CTL MD45 induced the cell surface
expression of scFv fragments, which is recognized by anti-id MoAb
MK2–23 elicited with the parental MoAb. In agreement with
Figure 6. FACS analysis of scFv763.74-gR chimeric receptor
expression on transfected MD45.1F1 T cells. MD45.1F1 cells
transduced with the chimeric scFv763.74-γR DNA were incubated with
the anti-id MoAb MK2–23 and with FITC-conjugated goat anti-mouse
IgG antibodies. Stained cells were analyzed by flow cytometry.
Untransfected MD45 cells and the unrelated anti-id MoAb TK7–371
(dotted line) were used as controls.
Figure 7. IL-2 secretion by scFv763.74-gR expressing MD45.D12
and MD45.1F1 T cell clones is increased by immobilized anti-id
MoAb MK2–23. MD45.D12 and MD45.1F1 T cell clones were cultured
for 48 h at 37°C in plates coated with the anti-id MoAb MK2–23 (2 µg
per ml). Then supernatant was harvested and tested for its IL-2 content
by ELISA. Untransfected MD45 cells were used as a control.
results obtained with chimeric receptors recognizing human breast,
gastrointestinal, ovarian, and renal carcinoma associated antigens
(Stancovski et al, 1993; Moritz et al, 1994; Hombach et al, 1998b),
CTL transduced with a chimeric receptor containing HMW-MAA
binding scFv fragments acquired the ability to recognize and lyse
HMW-MAA bearing melanoma cells. This phenomenon is specific
and mediated by the transfected chimeric receptor, as transfected
CTL did not lyse HMW-MAA negative melanoma cells and
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Figure 8. Enhancement by anti-id MoAb MK2–23 of the
cytotoxicity of scFv763.74-gR expressing MD45.D12 and MD45.1F1
T cell clones. MD45.D12 and MD45.1F1 T cell clones were incubated
for 48 h at 37°C in plates coated with anti-id MoAb MK2–23 (2 µg
per ml). Cells were then harvested and incubated for 16 h at 37°C with
51Cr labeled HMW-MAA1 SK-MEL-5 melanoma cells (5 3 103 per
well). Untransfected MD45 cells and unrelated anti-id MoAb TK7–
371 were used as controls. Released radioactivity was measured in the
supernatant. (A) Data represent the mean percentage of specific lysis 6 SD
at an effector/target ratio (E/T) of 10:1. (B) Data represent different E/T
ratios of the mean specific cytotoxicity of transfected T cell clones
and untransfected MD45 cells preactivated with anti-id MoAb MK2–23
(2 µg per ml).
parental CTL did not lyse HMW-MAA bearing melanoma cells.
The extent of specific lysis of HMW-MAA bearing melanoma cells
by transfected CTL was, however, low, as it was at most 10%.
This study has shown that the cytolytic activity of transfected
MD45 cells can markedly be increased following an in vitro
incubation with insolubilized HMW-MAA or with an insolubilized
anti-id MoAb, which recognizes an idiotope expressed on the
HMW-MAA binding scFv used to construct the chimeric receptor.
It is not unexpected that immobilization of the anti-id MoAb or
HMW-MAA is required in order to enhance the cytolytic activity
of CTL transfected with the chimeric receptor since cross-linking
of the Fc receptor subunit has been shown to be required to
trigger its signaling pathway (Wirthmu¨ller et al, 1992). The use of
immobilized anti-id MoAb to enhance the cytotoxic activity of
transfected CTL appears to be preferable to that of insolubilized
TAA as anti-id MoAb with well standardized characteristics can be
easily prepared in large amounts. An additional potential advantage
of anti-id MoAb is represented by their potential use in combination
with a cross-linking agent for in vitro stimulation of transfected
CTL. TAA, however, may represent a very useful alternative to
stimulate transfected CTL when anti-id MoAb are not available.
The lytic activity of the transfected MD45 cells following
Figure 9. Concentration-dependent enhancement by anti-id MoAb
MK2–23 of the cytotoxicity of scFv763.74-gR expressing MD45.G11
T cell clone. MD45.G11 T cells were incubated for 48 h at 37°C in
plates coated with different amounts of anti-id MoAb MK2–23. Cells were
then harvested and incubated for 16 h at 37°C with 51Cr-labeled HMW-
MAA1 SK-MEL-5 melanoma cells (5 3 103 cells per well). Released
radioactivity was measured in the supernatant. Data represent the mean
percentage of specific lysis 6 SD at an effector/target ratio of 10:1. The
unrelated anti-id TK7–371 and untransfected MD45 cells were used
as controls.
Figure 10. Enhancement by melanoma cells Colo 38, HMW-MAA
and anti-id MoAb MK2–23 of the cytotoxicity of scFv763.74-gR
expressing MD45.G11 T cell clones. MD45.G11 T cells were incubated
for 48 h at 37°C with melanoma cells Colo 38, with HMW-MAA bound
to MoAb 225.28 coated plate, with soluble anti-id MoAb MK2–23 (10 µg
per ml), with soluble anti-id MK2–23 (10 µg per ml) plus goat anti-mouse
IgG antibodies (10 µg per ml) or with immobilized anti-id MoAb MK2–
23 (10 µg per ml). Cells were then harvested and incubated for 16 h at
37°C with 51Cr-labeled HMW-MAA1 SK-MEL-5 melanoma cells. Data
represent the mean percentage of specific lysis 6 SD at an effector/target
ratio of 10:1. Untransfected MD45 cells were used as controls.
incubation with the insolubilized HMW-MAA or anti-id MoAb
MK2–23 was tested at a 10:1 effector/target ratio, in order to
resemble the in-vivo situation. Under these experimental conditions,
the transfected MD45 cells displayed a higher lytic activity than
tumor infiltrating lymphocytes targeted to ovarian carcinoma cells
by a chimeric receptor (Hwu et al, 1993), but lower than that of
peripheral blood lymphocytes targeted to renal carcinoma cells by
a chimeric receptor (Weijtens et al, 1996). These differences may
reflect the characteristics of the three types of effector cells and/or
of target cells. We favor the possibility of differences in effector
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cells, as MD45 cells targeted to colon carcinoma cells by a chimeric
receptor lysed target cells to an extent similar to that we have
observed following a 48 h incubation with the insolubilized antigen
(Hombach et al, 1998b). If our hypothesis is correct, it will be
interesting to investigate the effect of in vitro stimulation with
insolubilized TAA or with anti-id MoAb on the cytolytic activity of
tumor-infiltrating lymphocytes and peripheral blood lymphocytes.
Two results of our study are noteworthy from a methodologic
view point. First, anti-id MoAb represent useful reagents to identify
and isolate scFv fragments in soluble form as well as cells expressing
scFv following transfection with the chimeric receptor. Further-
more, in combination with cytofluorometric analysis anti-id MoAb
provide a simple and rapid method to select transfected clones with
a defined level of expression of the chimeric receptor. Second,
capture of a TAA from a cell lysate by a MoAb coated plate
provides an easy and simple approach to prepare insoluble TAA to
enhance the cytolytic activity of transfected CTL. If found to work
in other antigenic systems, this approach will eliminate the need
of time consuming and laborious procedures to purify TAA.
Although tumor-specific chimeric receptors can drive autologous
T cells to accumulate at the tumor site in vivo (Hwu et al, 1995),
the cytolytic activity of grafted T cells may be low. Furthermore,
the presence of high amounts of soluble TAA may prevent antigen-
driven cellular activation upon specific receptor cross-linking. This
potential limitation in the application of chimeric T cell receptors
in immunotherapy of malignant diseases may be overcome by
taking advantage of the marked enhancement of the cytotoxic
activity of transfected CTL by cross-linked anti-id MoAb we have
described in this study. Serum concentrations of soluble TAA,
however, do not inhibit the localization of radiolabeled anti-
HMW-MAA MoAb in melanoma lesions (Ferrone et al, 1988).
We do not expect efficient blocking of the chimeric receptor by
such low concentrations of soluble antigen in cells that express high
copy numbers of the chimeric receptor after retroviral transduction.
Retroviral transduction studies are now underway to prove the
cytolytic efficacy of peripheral blood cells equipped with the
scFv763.74-γ chimeric receptor and to evaluate the feasibility of
this approach in the immunotherapy of disseminated melanoma.
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